{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036838","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.111690+00:00","generated_at":"2026-05-24T23:43:08.356173+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corbus reports Q4 net loss $9.5M, cash $149.1M; pipeline updates on CRB-701, CRB-913, CRB-601","bullets":["Net loss Q4 2024 $9.5M ($0.78/share) vs $8.0M ($1.81/share) in Q4 2023; full-year loss $40.2M ($3.68/share).","Cash and investments $149.1M at Dec 31, 2024; expected to fund operations through Q3 2027.","CRB-701 (Nectin-4 ADC) Phase 1 shows safety and responses in HNSCC, cervical, and mUC; FDA Fast Track for metastatic cervical cancer.","CRB-913 obesity Ph1 SAD/MAD first dosing expected March 2025; CRB-601 first patient dosed Dec 2024, dose escalation Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036838","json":"https://secwatch.observer/filing/0000950170-25-036838.json","markdown":"https://secwatch.observer/filing/0000950170-25-036838.md","text":"https://secwatch.observer/filing/0000950170-25-036838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/0000950170-25-036838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/crbp-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:43:08.356173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}